SyneuRx International (Taiwan) Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Guochuan Emil Tsai

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

SyneuRx International (Taiwan) (GTSM:6575) Is In A Good Position To Deliver On Growth Plans

Mar 10

We Think SyneuRx International (Taiwan) (GTSM:6575) Can Afford To Drive Business Growth

Nov 25

CEO

Guochuan Emil Tsai

no data

Tenure

Mr. Guochuan Emil Tsai, MD PhD MAS serves as Chairman and Chief Executive Officer of SyneuRx International (Taiwan) Corp. Guochuan Emil Tsai is an Assistant Professor at Harvard Medical School. Guochuan Em...

SyneuRx International (Taiwan) Management

Management criteria checks 0/4

Key information

Recent management updates

Less than half of directors are independent

Less than half of directors are independent

SyneuRx International (Taiwan) Corp., Annual General Meeting, Jun 30, 2021

Recent updates

SyneuRx International (Taiwan) Corp.(TPEX:6575) dropped from S&P Global BMI Index

Less than half of directors are independent

SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

Less than half of directors are independent

SyneuRx™ International Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

SyneuRx International (Taiwan) Corp., Annual General Meeting, Jun 30, 2021

SyneuRx International (Taiwan) (GTSM:6575) Is In A Good Position To Deliver On Growth Plans

New 90-day high: NT$49.60

New 90-day low: NT$45.00

We Think SyneuRx International (Taiwan) (GTSM:6575) Can Afford To Drive Business Growth

CEO

Tenure